Bridging the gap between innovators, investors, healthcare and patients. Proven Connect is the translational arm of the charity Prostate Cancer Research (PCR).
Proven Connect bridges the gap between industry, investors, health providers and patients.
Born of 30 years experience in prostate cancer research, Proven Connect aims to support the commercialisation of prostate cancer innovations through investment, expertise in academic and translational research and a deep understanding of patient needs.
Prostate cancer is the most common cancer in men and as populations around the world age, the incidence of cases will increase. Through increasing funding and support for cutting edge research Proven Connect aims to relieve the burden of the disease for men, their families and wider society. All profits raised through Proven Connect will be invested back into prostate cancer.
If you would like to work with Proven Connect please contact us.
Investors
Support investors, from seed funders to late stage VC’s, to back promising new opportunities for investment in prostate cancer.
Proven Connect’s business model is based on the premise that only by working through strategic partnerships can we hope to transform the healthcare of men with prostate cancer.
Proven Connect is looking to work with organizations that share the same values and can bring finance, scientific expertise, clinical and patient knowledge, and/or commercial solutions to help us meet our goals. Our current list of partners is listed below.
If you are interested in a partnership with Proven Connect click below.
Proven Connect bridges the gap between industry, investors, health providers and patients. Established in 2021, Proven Connect is the translational arm of the charity Prostate Cancer Research (PCR).